Limited tools are available for identifying, diagnosing, and treating cognitive dysfunction from Alzheimer disease.
Use of benzodiazepines, Z-drugs, or other anxiolytics was not associated with incident dementia in either the cohort or nested case-control design.
Closer adherence to the alternative Mediterranean diet is associated with a reduced risk for cognitive decline, but not with slower decline in cognitive function.
Plasma phosphorylated tau181 (P-tau181) may aid in the diagnosis of Alzheimer disease (AD), a study in Natural Medicine suggests.
Sleep-disordered breathing is associated with changes in the brain, including amyloid deposition in brain regions typically involved in Alzheimer disease.
Primary care physicians believe they are on the front lines of dementia care, but many feel unprepared.
There is no evidence for an association between cerebral β-amyloid deposition, a marker of Alzheimer disease, and intracranial atherosclerotic plaque or stenosis.
Higher flavonol intake through food sources, mostly fruits and vegetables, may protect against the development of Alzheimer disease.
Topline data were announced from the phase 2/3 DIAN-TU study of solanezumab (Eli Lilly) and gantenerumab (Genentech) in patients at risk for or with dominantly inherited Alzheimer disease.
The Food and Drug Administration (FDA) has approved updates to the prescribing information for Belsomra® (suvorexant; Merck) to include study findings for the treatment of insomnia in patients with mild to moderate Alzheimer disease.